Sarah L. Pass

Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014

Kurt G. Pike, Karine Malagu, Marc Hummersone et al. · Bioorganic & Medicinal Chemistry Letters · 2013 · 206 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R)

Sébastien L. Degorce, Scott Boyd, Jon Curwen et al. · Journal of Medicinal Chemistry · 2016 · 33 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery of AZD3147: A Potent, Selective Dual Inhibitor of mTORC1 and mTORC2

Kurt G. Pike, Jeff Morris, Linette Ruston et al. · Journal of Medicinal Chemistry · 2015 · 28 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours

Bernard Barlaam, Sabina Cosulich, Sébastien L. Degorce et al. · Bioorganic & Medicinal Chemistry Letters · 2014 · 19 citations · Full text

Medicine, Oncology, Pharmacology +10

Abstract 917: AZD2014, a dual mTORC1 and mTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+ breast cancer

Sylvie M. Guichard, Zoë Howard, Dan Heathcote et al. · Cancer Research · 2012 · 17 citations

Medicine, Oncology, Pharmacology +13